(Q33391566)

26 July 2017

title

Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China (English)

1 reference

26 July 2017

Bortezomib Plus Thalidomide for Newly Diagnosed Multiple Myeloma in China (English)

1 reference

21 June 2024

0 references

Shi-Lun Chen

1

1 reference

26 July 2017

Bin Jiang

2

1 reference

26 July 2017

Lu-Gui Qiu

3

1 reference

26 July 2017

Li Yu

4

1 reference

26 July 2017

Yu-Ping Zhong

5

1 reference

26 July 2017

Wen Gao

6

1 reference

26 July 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20734318

21 June 2024

publication date

23 August 2010

1 reference

full work available at URL

26 July 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ar.21218

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20734318

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Far.21218

21 June 2024

1 reference

https://onlinelibrary.wiley.com/doi/full/10.1002/ar.21218

21 June 2024

1 reference

21 June 2024

published in

The Anatomical Record

1 reference

26 July 2017

volume

293

1 reference

26 July 2017

issue

10

1 reference

26 July 2017

page(s)

1679-1684

1 reference

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature

26 July 2017

cites work

1 reference

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

21 January 2018

1 reference

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

21 January 2018

1 reference

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

Multiple myeloma: evolving genetic events and host interactions

21 January 2018

1 reference

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma

21 January 2018

1 reference

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

21 January 2018

1 reference

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

21 January 2018

1 reference

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration

21 January 2018

1 reference

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

21 January 2018

1 reference

Treatment of multiple myeloma

21 January 2018

2

1 reference

Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma

21 June 2024

10

1 reference

An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma

21 June 2024

15

1 reference

Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma

21 June 2024

20

1 reference

21 June 2024

Identifiers

DOI

10.1002/AR.21218

1 reference

26 July 2017

1 reference